Optimized clinical trials are the key to delivering successful and powerful medicines to the modern world. Though there are a variety of solution providers, ObioHealth is an innovator in this space. ObvioHealth is an end-to-end virtual research organization (VRO), combining the clinical excellence of the best CROs with pioneering technology to optimize clinical trials at every stage and touchpoint. The company has been innovating decentralized study designs since 2017, leveraging ObvioGo®—their proprietary DCT platform and app—as well as an in-house virtual site team and expert clinicians to improve patient engagement and deliver stronger evidence to trial sponsors. “Our DCT solutions are powered by ObvioGo™, a highly-configurable and AI-enabled platform that accommodates a broad spectrum of trial protocols—from heavily site-based to fully virtual. This flexibility gives you the freedom to design a clinical trial that will deliver stronger therapeutic evidence.”

Today, ObvioHealth is on a mission to conduct innovative and efficient trials that deliver stronger evidence for better health outcomes. The company use technology to develop more precise and accessible measurement tools to capture more robust and accurate data—so life-improving innovations can get to market faster. The company’s ObvioGo is a powerful and flexible technology has been designed to capture, integrate, and analyze more accurate multi-source data, empowering clinical science teams to generate stronger therapeutic evidence with ease. Today’s DCT technology helps to reduce patient burden, but it hasn’t addressed the problems of inaccuracy and the interoperability needed to deliver robust outcomes and endpoints. ObvioGo’s next-generation DCT platform and mobile app incorporate best-in-class digital instruments, AI, and machine learning with intuitive interfaces and seamless integrations to deliver more robust and reliable clinical outcomes.

The company’s fully configurable study design tools have modular components that easily adapt to each project’s unique parameters, across therapeutic areas and geographies. The solution not only enables to effortlessly configure protocol-specific eConsent, screening, eCOA, and ePRO components but also to test, preview, and publish study screens to the ObvioGo mobile app for sponsor review. Users can also easily implement mid-study change orders with flexibility, empowered by real-time learning. ObvioGo’s outcomes capture and assessment capabilities include AI-assisted technologies that facilitate the collection of more accurate data from all users. ObvioHealth combine all the excellence of the best clinical research organizations with industry-leading technology—delivering the same services as a traditional CRO but optimized for a decentralized environment.

ObvioGo’s cloud native platform securely stores all data, integrates with enterprise clinical research systems, and can be deployed globally, empowering clinical science teams to generate stronger therapeutic evidence. It enables to secure gating with permissions-based functionalities enables sites, labs, and other stakeholders to enter data directly into the platform. The solution’s real-time data processing with automatic data cleaning, auto-edit checks, and advanced query resolutions reduces time to database lock makes clinical trials easier than ever. In addition, this enables seamless integration with EDC, CTMS, RTSM, and eTMF—as well as EHRs, labs, and imaging—enables richer and deeper analyses. “ObvioHealth was built from the ground up to ensure you get both. You won’t find our model elsewhere: DCT strategy, powerful tech, and a full-service site team—under one virtual roof.”

While traditional informed consent processes are burdensome for participants and sites, prone to errors, and lack flexibility when reconsent is necessary.  ObvioHealth’s eConsent is designed to remove friction and support users. With increased flexibility for sponsors, improved adaptability for sites, and an engaging experience for patients, our eConsent sets your clinical trial on the path to success from the start. 

ObvioHealth successfully conducted a clinical trial for RedHill Biopharma to test the safety and efficacy of an oral medication for the treatment of COVID-19 symptoms. We designed this decentralized study to be conducted where the majority of patients recover from illness—in their homes. When the trial was launched in 2021, its unique combination of home health visits, electronic patient-reported outcomes (ePRO), and remote monitoring devices was pioneering—COVID-19 studies were typically conducted inside hospitals.

ObvioHealth has been innovating clinical trials since 2017, when the team launched one of the first-ever DCT platforms with a mobile app. Today, the company is an industry leader, designing and running DCTs across the globe that generate more robust and accurate data.